$VNRX News

VolitionRx Limited (VNRX) Q2 2026 Earnings Call Transcript

VolitionRX Reports Q2 2026 Results: Full Earnings Call Transcript

VolitionRX Q2 EPS $(0.85) Misses $(0.57) Estimate, Sales $398.657K Miss $482.667K Estimate

VolitionRx Announces That Results Utilizing Its Lateral Flow Prototype Are Highly Correlated With Results Utilizing Its Legacy Automated Nu.Q® NETs Test In Critically Ill Sepsis Patients

Volition Reports Publication of First Peer Reviewed Paper on New Capture-Seq™ Liquid Biopsy Technology

Volition Advances Nu.Q® NETs Platform Towards Commercialization

VolitionRx (VNRX) Stock Gets Fair Value Boost As Analysts Split On Nu.Q Execution

VolitionRx Announces Data Showing the Prognostic Value of its Nu.Q® Cancer Test

VolitionRx Publishes Paper On The Prognostic Value Of Its Nu.Q Cancer Assay In Newly Diagnosed Lung Cancer Patients

VolitionRx Announces Collaboration with Sysmex

VolitionRx Announces Pricing of $4.6 Million Public Offering

VolitionRx Files New Patent Protecting its Nu.Q® NETs Test for Ebola Triage and Treatment Monitoring

VolitionRx Highlights Commercial Momentum and Multi-Pillar Execution Across $27+ Billion Total Addressable Markets

VolitionRx Limited (VNRX): 7 Best Rated Penny Stocks to Buy According to Wall Street Analysts

VolitionRX Ltd (VNRX) Q1 2026 Earnings Call Highlights: Revenue Surge and Strategic ...

VolitionRx Limited (VNRX) Q1 2026 Earnings Call Transcript

VolitionRx Limited Q1 2026 Earnings Call Summary

Full Transcript: VolitionRX Q1 2026 Earnings Call

VolitionRx Limited Announces First Quarter 2026 Financial Results and Business Update

VolitionRX Q1 EPS $(0.97) Misses $(0.75) Estimate, Sales $985.076K Beat $426.600K Estimate